Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 3
Submit an article Journal homepage
240
Views
0
CrossRef citations to date
0
Altmetric
Perspective

Uncertain Prognosis for High-Quality Diagnostics: Clinical Challenges, Economic Barriers and Needed Reforms

Mark R Trusheim1 MIT Sloan School of Management, Building E62-518, 100 Main St, Cambridge, MA02139-4307, USAView further author information
,
MJ Finley Austin2 AstraZeneca, Wilmington, DE, USAView further author information
,
Carsten Rausch3 Roche Professional Diagnostics, Rotkreuz, [email protected]View further author information
&
Ernst R Berndt1 MIT Sloan School of Management, Building E62-518, 100 Main St, Cambridge, MA02139-4307, USAView further author information
Pages 325-334 | Published online: 11 Feb 2013

References

  • European Diagnostic Manufacturers Association. Annual Report 2009. EDMA, Brussels, Belgium, 11–13 (2009).
  • Trusheim MR , BerndtER, DouglasFL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov.6 , 287–293 (2007).
  • Hu SX , FosterT, KieffaberA et al. Pharmacogenomics and personalized medicine: mapping of future value creation. Biotechniques 39(Suppl. 10) , S1–S6 (2005).
  • Aspinall MG , HamermeshRG. Realizing the promise of personalized medicine. Harvard Bus. Rev.85(10) , 108–117 (2007).
  • Spear BB , Heath-ChiozziM, HuffJ. Clinical application of pharmacogenetics. Trends Mol. Med.7(5) , 201–204 (2001).
  • US Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med.151(10) , 716–726 (2009).
  • Gaisser S , HopkinsMM. The phantom menace of gene patents. Nature458(7237) , 407–408 (2009).
  • Peeling RW , SmithPG, BossuytPM. A guide for diagnostic evaluations. Nat. Rev. Microbiol.8(Suppl. 12) , S2–S6 (2010).
  • TDR Diagnostics Evaluation Expert Panel, Banoo S, Bell D et al. Evaluation of diagnostic tests for infectious diseases: general principles. Nat. Rev. Microbiol.8(Suppl. 12) , S17–S29 (2010).
  • Temple R . Enrichment of clinical study populations. Clin. Pharmacol. Ther.88(6) , 774–778 (2010).
  • Ikediobi ON , ShinJ, NussbaumRL et al. Addressing the challenges of the clinical application of pharmacogenetic testing. Clin. Pharmacol. Ther. 86(1) , 28–31 (2009).
  • Kirchheiner J , FuhrU, BrockmöllerJ. Pharmacogenetics-based therapeutic recommendations – ready for clinical practice? Nat. Rev. Drug Discov.4(8) , 639–647 (2005).
  • Lesko LJ , ZinehI, HuangSM. What is clinical utility and why should we care? Clin. Pharmacol. Ther.88(6) , 729–733 (2010).
  • Quinn B . Payers and the assessment of clinical utility for companion diagnostics. Clin. Pharmacol. Ther.88(6) , 751–754 (2010).
  • Shen B , HwangJ. The clinical utility of precision medicine: properly assessing the value of emerging diagnostic tests. Clin. Pharmacol. Ther.88(6) , 754–756 (2010).
  • deFilippi CR , de Lemos JA, Christenson RH et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA304(22) , 2494–2502 (2010).
  • Jarvik JG , HollingworthW, MartinB et al. Rapid magnetic resonance imaging vs radiographs for patients with low back pain: a randomized controlled trial. JAMA 289(21) , 2810–2818 (2003).
  • Miller P , KendrickD, BentleyE, FieldingK. Cost–effectiveness of lumbar spine radiography in primary care patients with low back pain. Spine27(20) , 2291–2297 (2002).
  • Barry MJ . Screening for prostate cancer – the controversy that refuses to die. N. Engl. J. Med.360(13) , 1351–1354 (2009).
  • Garrison LP Jr, Austin MJF. Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. Health Affairs25(5) , 1281–1290 (2006).
  • Phillips KA , Van Bebber S, Issa AM. Diagnostics and biomarker development: priming the pipeline. Nat. Rev. Drug Discov.5(6) , 463–469 (2006).
  • Woodcock J . Assessing the clinical utility of diagnostics used in drug therapy. Clin. Pharmacol. Ther.88(6) , 765–773 (2010).
  • Evans BJ . Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era. Clin. Pharmacol. Ther.88(6) , 749–751 (2010).
  • Hockett RD , CloseSL. Regulation of laboratory-developed tests: the case for utilizing professional associations. Clin. Pharmacol. Ther.88(6) , 743–745 (2010).
  • O‘Kane D . An outsider‘s viewpoint: the FDA should regulate clinical pharmacogenetic/genomic tests, but…. Clin. Pharmacol. Ther.88(6) , 746–748 (2010).
  • Garrison LP Jr, Austin MJF. The economics of personalized medicine: a model of incentives for value capture and creation. Pharmacoeconomics41 , 501–509 (2007).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.